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Introduction
The function of the 2 cyclooxygenase (COX) isoforms,
COX-1 and COX-2, in maintaining mucosal home-
ostasis and modulating inflammation in the digestive
tract remains uncertain. Enzymatic activities of these
COX isoforms produce prostaglandins (PGs) that play
a proinflammatory role by mediating fever, hyperalge-
sia, vascular permeability, and edema; they also stimu-
late diarrhea by promoting chloride secretion and
blocking sodium absorption in epithelial cells (1). Dur-
ing inflammation, dramatic increases in mucosal PG
synthesis correlate with the disease activity of human
inflammatory bowel diseases and experimental colitis
(2–4). However, PGs also play a protective role against
gastrointestinal injury (5) and downregulation of the
expression of proinflammatory cytokines (6, 7). Indeed,
experimental colitis can be attenuated by pretreatment
with exogenous PGs (3, 8), and prostaglandin E2 (PGE2)
plays a major role in the regeneration of the epithelial
crypts after dextran sodium sulfate (DSS)- and radia-
tion-induced intestinal damage in mice (9). Further-
more, inhibition of PG synthesis by indomethacin
induces acute and chronic enterocolitis in genetically
susceptible rats (10), which is in agreement with gas-
trointestinal ulceration seen in patients treated with
nonsteroidal anti-inflammatory drugs (NSAIDs) (11,
12). This effect is attributed to the inhibition of con-
stitutive mucosal PGs, which have cytoprotective prop-
erties (13). Similarly, active or passive immunization
with PGE2, PGE1, and prostacyclin (PGI2) induces gas-
trointestinal ulcers in rabbits (14, 15).
The relative contribution of COX-1 and COX-2 iso-
forms to the biologic activities of PGs in the gastroin-
testinal mucosa is less clear. Several observations led to
the hypothesis that inducible COX-2 drives the proin-
flammatory actions of PGs during mucosal injury,
whereas COX-1 regulates gastrointestinal homeostasis
through the synthesis of cytoprotective PGs (16). COX-
1 is responsible for the basal production of PGs under
normal gastric conditions (17), and its expression is not
affected by corticosteroids (18). In mice, COX-1 has
been reported to play a protective role against small
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To investigate roles in intestinal inflammation for the 2 cyclooxygenase (COX) isoforms, we deter-
mined susceptibility to spontaneous and induced acute colitis in mice lacking either the COX-1 or
COX-2 isoform. We treated wild-type, COX-1–/–, COX-2–/–, and heterozygous mice with dextran sodium
sulfate (DSS) to provoke acute colonic inflammation, and we quantified tissue damage, prostaglandin
(PG) E2, and interleukin-1β. No spontaneous gastrointestinal inflammation was detected in mice
homozygous for either mutation, despite almost undetectable basal intestinal PGE2 production in
COX-1–/– mice. Both COX-1–/– and COX-2–/– mice showed increased susceptibility to a low-dose of DSS
that caused mild colonic epithelial injury in wild-type mice. COX-2–/– mice were more susceptible than
COX-1–/– mice, and selective pharmacologic blockade of COX-2 potentiated injury in COX-1–/– mice. At
a high dose, DSS treatment was fatal to 50% of the animals in each mutant group, but all wild-type
mice survived. DSS treatment increased PGE2 intestinal secretion in all groups except COX-2–/– mice.
These results demonstrate that COX-1 and COX-2 share a crucial role in the defense of the intestinal
mucosa (with inducible COX-2 being perhaps more active during inflammation) and that neither iso-
form is essential in maintaining mucosal homeostasis in the absence of injurious stimuli.
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intestinal (9) and colonic (19) mucosal injury through
the synthesis of PGs that promote epithelial regenera-
tion. In contrast, COX-2 expression is induced during
inflammation (17), and its expression is inhibited by
endogenous glucocorticoids (18).
COX-2 gene and protein expression is stimulated in
macrophages and other cell types by proinflammatory
cytokines like IL-1 (20) and TNF-α (21, 22). This
process is mediated in colonic epithelial cells by the
activation of the nuclear factor NF-κB (23). COX-2
overexpression in rat intestinal epithelial cells inhibits
the expression of cytoprotective heat-shock proteins
(24). Based on these observations, some researchers
have attributed the anti-inflammatory action of
NSAIDs to the inhibition of COX-2; and harmful
effects of NSAIDs on the gastrointestinal mucosa are
attributed to the blockade of COX-1 activity (25, 26).
This association of COX-2 with inflammatory events
led to the development of selective COX-2 inhibitors
expected to display systemic anti-inflammatory prop-
erties, while avoiding gastrointestinal toxicity.
Selective COX-2 inhibitors reduce air pouch and foot
pad experimental inflammation in animal models
without causing gastrointestinal injury, in contrast to
classical NSAIDs (27, 17). Recently, a clinical trial in
patients with osteoarthritis emphasized the safety of
the selective COX-2 inhibitor rofecoxib, which caused
significantly less gastroduodenal ulceration than the
NSAID ibuprofen (28). However, COX-2 inhibitors
have also been shown to be harmful when there is pre-
existing gastrointestinal inflammation, because they
delay gastric ulcer healing in mice (29) and exacerbate
colonic mucosal inflammation in rats (30). These toxic
effects suggest a protective role for mucosal COX-2 in
gastrointestinal inflammation.
COX-1 mediates epithelial regeneration in a model of
irradiation-induced intestinal injury in mice (9), which
supports the cytoprotective role attributed to COX-1 in
gastrointestinal inflammation. However, COX-1–defi-
cient mice do not exhibit any evidence of spontaneous
gastric injury in the absence of an inflammatory stim-
ulus and, surprisingly, are more resistant than their
wild-type (WT) littermates to indomethacin-induced
gastric damage (31). These observations, and the fact
that the majority of patients receiving NSAIDs do not
develop clinically significant gastrointestinal ulcera-
tions, suggest that COX-1 does not exclusively mediate
gastrointestinal protection, and instead it acts in con-
cert with other redundant, protective molecules.
The aim of this study was to investigate the relative
roles of COX-1 and COX-2 isoforms in spontaneous
and induced inflammation of the intestinal mucosa.
So far, all the studies related to the function of COX-1
and COX-2 in intestinal inflammation have involved
pharmacologic inhibitors, which may not be entirely
selective and have potential nonspecific side effects. As
a complementary approach to selective pharmacologic
blockade, we used mice genetically lacking either COX-
1 (31) or COX-2 (32) expression. We investigated the
presence of spontaneous colitis as well as the relative
severity of acute DSS-induced colitis in the absence of
each of the COX isoforms; we compared heterozygous
and WT littermates and the inhibition of both COX
isoforms by partial pharmacologic blockade of COX-
2–/– in COX-1–/– mice.
Methods
Mice. WT, COX-1–/– homozygous, COX-1+/– heterozygous,
COX-2–/– homozygous, and COX-2+/– heterozygous out-
bred C57black6/SV129 mice were maintained on a 12-
hour light/dark schedule in filter top isolators with
autoclaved water under specific pathogen-free (SPF)
conditions, and fed autoclaved standard laboratory
chow ad libitum. Genotypes of mice were determined
on DNA isolated from tails, using previously described
protocols (31, 32). Genomic DNA totaling 8–10 µg was
digested with BamHI (COX-1) or SacI (COX-2) overnight
and applied to a 0.8% agarose gel. After separation using
agarose gel electrophoresis, the DNA was transferred to
Hybond nylon membrane. Membranes were probed
with 32P-labeled specific probes for COX-1 or COX-2.
Membranes were then washed and exposed overnight to
Kodak XAR film (Eastman Kodak, Rochester, New
York, USA) with an intensifying screen.
Assessment of spontaneous gastrointestinal inflammation.
Clinical observations (twice weekly) included evaluation
of body weight, diarrhea, occult blood in the stools
(Hemoccult testing; SmithKline Beecham Pharmaceu-
ticals, Philadelphia, Pennsylvania, USA), and perianal
inflammation. Mice were killed at 4 different ages (4, 8,
12, and 16 weeks). Blinded gross observations and
coded histology scores were performed on the colon,
cecum, distal ileum, proximal jejunum, and stomach
(glandular and squamous regions). Tissue IL-1β con-
centrations were evaluated by ELISA (Genzyme Phar-
maceuticals, Cambridge, Massachusetts, USA) and tis-
sue PGE2 concentrations by RIA (PerSeptive Biosystems,
Framingham, Massachusetts, USA) in snap-frozen tis-
sues homogenized in PBS buffer containing the follow-
ing antiproteases: 50 µg/mL antipain-dihydrochloride,
2 µg/mL aprotinin, and 0.5 µg/mL leupeptin (Roche
Molecular Biochemicals, Indianapolis, Indiana, USA).
Induction of acute colitis. Mice 12–15 weeks old were fed
DSS (TdB Consultancy AB, Uppsala, Sweden) in their
drinking water, according to the protocol of Cooper et
al. (33). Three separate studies were conducted. In the
first (high-dose DSS), the survival rate was evaluated in
5 WT, 6 COX-1–/–, 7 COX-1+/–, 6 COX-2–/–, and 8 COX-2+/–
mice treated with high-dose DSS (10%) continuously
administered in the drinking water for 5 days. In the sec-
ond (low-dose DSS), 14 WT, 7 COX-1–/–, 7 COX-2–/–, 15
COX-1+/–, and 11 COX-2+/– mice received a low dose of
DSS (2.5%) for 5 days. Control groups consisting of 6
WT, 5 COX-1+/–, 3 COX-2+/–, and 2 COX-2–/– mice were fed
water without DSS. The third (pharmacologic inhibition
of COX-2 in COX-1–/– mice), the selective COX-2
inhibitor NS-398 (Cayman Chemical, Ann Arbor, Michi-
gan, USA) was administered to WT, COX-1–/–, and COX-
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2–/– mice starting 2 hours before treatment with 2.5%
DSS for 5 consecutive days until the end of DSS treat-
ment. Control WT, COX-1–/–, and COX-2–/– mice treated
with 2.5% DSS received the vehicle for NS-398 under the
same conditions. Ten to 15 mice per group were used.
NS-398 was dissolved in DMSO and the stock solution
was diluted in saline just before administration. NS-398
(1 mg/kg) was injected intraperitoneally every 8 hours
following a previously described protocol that reported
significant inhibition of colonic PGE2 production in
DSS-treated mice (9).
Assessment of inflammation in DSS-treated mice. Daily
clinical evaluations included measurement of water
consumption and body weight, evaluation of stool
consistency, and the presence of blood in the stools. A
previously validated clinical score ranging from 0 to 4
(33) was calculated using the parameters of weight
loss, stool consistency, and the presence or absence of
fecal blood. Mice were killed at day 5, blood was col-
lected by intracardiac puncture, and the liver and
spleen weights were measured. The colon was removed
and divided for histology and for evaluation of PGE2
and cytokine secretion. Peripheral blood hemoglobin
content and white blood cell count were analyzed
using a blood cell counter (Baker Instruments Corp.,
Allentown, Pennsylvania, USA) and hematocrits were
measured by centrifugation of heparinized microcap-
illary tubes (Fisher Scientific Co., Pittsburgh, Pennsyl-
vania, USA) at 10,000 rpm.
Histology. Samples of proximal colon (2–3 cm from
the ileocecal junction) were fixed in 10% buffered for-
malin and stained with hematoxylin and eosin. The
histological examination was performed in a blinded
fashion by 2 different coauthors (O. Morteau and L.A.
Dieleman) using a scoring system previously validat-
ed and described (34). Three independent parameters
were measured: severity of inflammation (0–3: none,
slight, moderate, severe), depth of injury (0–3: none,
mucosal, mucosal and submucosal, transmural), and
crypt damage (0–4: none, basal 1/3 damaged, basal
2/3 damaged, only surface epithelium intact, entire
crypt and epithelium lost). The score of each parame-
ter was multiplied by a factor reflecting the percent-
age of involvement (1–4: 0%–25%, 26%–50%, 51%–75%,
76%–100%) and added. The maximum possible score
is 40. In addition, the actual percentage of mucosal
surface area ulcerated was estimated.
PGE2 and cytokine secretion. The stomach, cecum, and
colon were removed, opened longitudinally, washed in
PBS buffer containing penicillin, streptomycin, and
fungizone (P/S/F, 100 U/mL), and then kept in cold
serum-free media (RPMI 1640 1× with P/S/F). The
organs were cut into small pieces in a Petri dish con-
taining fresh media, and 100 mg of tissue fragments
were incubated at 37°C in 1 mL of fresh media for 24
hours as described (35). Culture supernatants were har-
vested and assayed for PGE2 secretion by RIA (PerSep-
tive Biosystems) and for IL-1β and IL-10 secretion by
ELISA (Genzyme Pharmaceuticals).
Statistical analysis. The data were expressed as the mean
± SEM. Parametric data were analyzed using the non-
paired Student’s t-test: a P < 0.05 was considered signif-
icant. Nonparametric data were analyzed by ANOVA.
Results
Genetic absence of either COX-1 or COX-2 expression does not
affect the integrity of the normal gastrointestinal mucosa.
None of the mice exhibited any clinical manifestations
(diarrhea, rectal bleeding, rectal prolapse, fecal occult
blood, or anemia) associated with spontaneous gas-
trointestinal inflammation. No abnormalities were
observed during gross examination of the gastroin-
testinal tract (glandular and squamous parts of the
stomach, duodenum, jejunum, ileum, cecum, colon,
and rectum) from WT, COX-1–, or COX-2–deficient
mice. Blinded histologic observation of the same
organs did not reveal any evidence of mucosal or sub-
mucosal inflammation or epithelial injury. Colonic
myeloperoxidase activity was similar in the WT and
knockout mice (data not shown), consistent with the
absence of neutrophils in both groups. However, 2 out
of the 10 COX-2–deficient mice developed peritonitis
associated with serosal infiltration by mononuclear
cells and neutrophils. This peritonitis has been previ-
ously observed in COX-2–deficient mice, but not in
COX-1–deficient mice (32). Histologic evidence of
mucosal inflammation was not found in these 2 mice.
Basal PGE2 but not IL-1βproduction is altered in the intestine
of mice lacking COX-1. PGE2 in colonic tissues from COX-
1–/– mice was barely detectable and significantly (P <
0.01) lower than in colonic tissues from WT or COX-2–/–
mice, which showed similar PGE2 production (Figure 1).
A similar lack of constitutive PGE2 production was
observed in the stomach, duodenum, jejunum, ileum,
and cecum of COX-1–/– mice, whereas levels were normal
in COX-2–/– mice (data not shown). Basal IL-1β produc-
tion was very low in the different segments of the gas-
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Figure 1
Basal PGE2 concentration in unstimulated colonic tissues from WT
and COX-1– and COX-2–deficient mice. Tissue PGE2 concentrations
were measured by RIA in snap-frozen tissues homogenized in PBS
buffer containing the following antiproteases: 50 µg/mL antipain-
dihydrochloride, 2 µg/mL aprotinin, and 0.5 µg/mL leupeptin. Mean
± SEM, n = 7. *P < 0.05 versus WT and COX-2–/–, n = 7.
trointestinal tract and was similar in all mice, regardless
of tissue PGE2 levels (data not shown). These data con-
firm the lack of spontaneous gastrointestinal inflam-
mation in SPF mice lacking constitutive mucosal PGE2,
and they support the notion that constitutive expression
of COX-1 is required for basal production of PGE2.
High-dose DSS treatment reduces survival in mice genetically
lacking COX-1 or COX-2 expression. Treatment with high-
dose (10%) DSS in the drinking water induced fulminant
colitis characterized by the dramatic appearance of
bloody diarrhea. Loss of body weight was significantly (P
< 0.05) but transiently greater on day 3 in COX-2–/– mice,
when compared with other DSS-treated groups: loss of
12.1 ± 2.4% of original weight (COX-2–/–), 4.9 ± 1.7% (WT),
2.8 ± 1.4% (COX-1–/–), 4.9 ±1.2% (COX-1+/–), and 5.3 ± 0.8%
(COX-2+/–). The clinical inflammatory score was also sig-
nificantly, but transiently (days 1 and 2), higher in the
COX-2–/– mice when compared with DSS-treated WT: 1.3
± 0.4 (COX-2–/–) versus 0.6 ± 0.1 (WT) (P < 0.05) (day 1); 2.2
± 0.3 (COX-2–/–) versus 1.1 ± 0.3 (WT) (P < 0.05) (day 2).
The percentage survival of COX-2–/– and COX-1–/– mice
decreased by day 4, dropped by day 5 to 50% (Table 1) and
was slightly decreased in the COX-1+/– heterozygous mice;
whereas all WT and COX-2+/– mice survived the full 5 days
of treatment. These results suggest that the onset of
severe colitis is accelerated in COX-2–/– mice, and that mice
lacking either inducible or constitutive COX isoforms
have increased mortality when compared with WT mice.
Genetic absence of COX-2 prevents the increase in colonic
PGE2 secretion induced by high-dose DSS treatment. DSS
treatment (10%) evoked at day 5 an increase in PGE2
colonic secretion in all DSS-treated groups except in
the COX-2–/– mice, when compared with water-treated
negative controls (Figure 2). Colonic secretion of PGE2
was significantly (P < 0.01) decreased in COX-2–/– mice
and attenuated in the 10% DSS-treated COX-2+/– mice
(Figure 2). Similar observations were made in the
inflamed cecum. However, gastric PGE2 secretion was
not increased in any of the DSS-treated mice (not
shown). These results confirm the lack of inducible
PGE2 secretion with colonic inflammation in COX-2–/–
mice and demonstrate an intermediate phenotype for
COX-2 heterozygous mice.
Genetic absence of COX-1 or COX-2 expression exacerbates
clinical abnormalities induced by low-dose DSS treatment.
Low-dose (2.5%) DSS treatment of WT mice for 5 days
was associated with no significant alterations in body
weight (Figure 3a) and only mild alterations in stool con-
sistency with no fecal blood or mortality. Water con-
sumption was similar in all groups (not shown). A sig-
nificant (P < 0.01) decrease in weight was observed in the
COX-2–/– mice on days 4 and 5 when compared with the
WT mice (Figure 3a). It is interesting to note that COX-
1+/– and COX-2+/– mice exhibited a nonsignificant
decrease in body weight by day 4 (COX-1+/–: 1.2 ± 1.0%,
COX-2+/–: 2.3 ± 1.7%, and WT: 0.2 ± 1.0%), which suggests
an intermediate phenotype in those mice.
The clinical score based on weight loss, stool consis-
tency, and presence of fecal blood was highest in the
COX-2–/– mice receiving low-dose DSS (Figure 3b),
reaching statistical significance when compared with
the WT mice (P < 0.01 from day 2 to day 5). COX-1–/–
mice also exhibited a significantly greater (P < 0.01)
clinical score than the WT mice on days 4 and 5, but
they had a lower clinical score than the COX-2–/– mice
(P < 0.05 at day 2). The clinical score was significantly
(P < 0.05) higher in the COX-2+/– heterozygous mice
than in the WT mice at day 4 (1.3 ± 0.3 versus 0.7 ± 0.1,
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Figure 2
Colonic PGE2 levels in 24-hour culture supernatants from either
untreated mice (water controls) or WT, heterozygous, or homozy-
gous mice for COX-1 or COX-2 deletion treated for 5 days with 10%
DSS. The colons were removed, opened longitudinally, washed in
PBS buffer containing penicillin, streptomycin, and fungizone (P/S/F,
100 U/mL) and kept in cold serum-free media (RPMI 1640 1× with
P/S/F). The organs were cut into small pieces in a Petri dish con-
taining fresh media and 100 mg of tissues were incubated at 37°C
in 1 mL of fresh media for 24 hours. Culture supernatants were har-
vested and assayed for PGE2 secretion by RIA. Mean ± SEM, n = 6. *P
< 0.05 versus water controls; +P < 0.05 versus COX-1+/–.
Table 1
Survival rate (%) with high-dose (10%) DSS treatment administered
for 5 days to either wild-type mice or mice homozygous (–/–) or het-
erozygous (+/–) for COX-1 or COX-2 deficiency
Genotype % survival
4 days 5 days
WT 100 (5/5) 100 (5/5)
COX-1–/– 100 (6/6) 50 (3/6)
COX-2–/– 83 (5/6) 50 (3/6)
COX-1+/– 100 (7/7) 86 (6/7)
COX-2+/– 100 (8/8) 100 (8/8)
Five to 8 mice per group were given 10% DSS in drinking water continuously
for 5 days, and survival was monitored.
P < 0.05). In addition, the clinical score was signifi-
cantly increased in the COX-1+/– heterozygous mice,
when compared with the WT mice at day 2 (0.8 ± 0.1
versus 0.4 ± 0.1, P < 0.05), day 4 (1.3 ± 0.2 versus 0.7 ±
0.1, P < 0.01), and day 5 (2.0 ± 0.2 versus 1.1 ± 0.2, P <
0.01). These results demonstrate a greater degree of
induced colitis in mice lacking COX-1 or COX-2 gene
expression with an intermediate disease in mice het-
erozygous for either COX isoform.
Genetic deficiency in COX-1 or COX-2
expression induces macroscopic changes
after low-dose DSS treatment. Macro-
scopic changes classically associated
with DSS treatment, including short-
ening of the colon, increase in colonic
weight and thickness, and increase in
spleen weight (36), were not seen in
WT mice treated with low-dose (2.5%)
DSS (Table 2). However, colonic short-
ening and splenomegaly were signifi-
cantly increased in DSS-treated COX-
1–/– and COX-2–/– mice (P < 0.05 and P
< 0.01, respectively), and the colon
weight/length ratio, a measurement
indicative of colonic edema and/or
hyperplasia, was significantly increased in DSS-treat-
ed COX-2–/– mice (P < 0.05) when compared with DSS-
treated WT mice (Table 2). Consistent with clinical
scores, COX-2–/– mice exhibited the most aggressive
injury, with intermediate values for COX-1–/– mice
treated with low-dose DSS.
Genetic deletion of COX-2 expression exacerbates hemato-
logic alterations induced by low-dose DSS treatment. At day
5, all groups of mice treated with low-dose (2.5%) DSS
exhibited a significant (P < 0.05) increase in peripheral
blood white blood cells when compared with water
controls (Table 2). COX-2–/– mice exhibited a significant
(P < 0.05) increase in leukocytosis and anemia relative
to DSS-treated COX-1–/– and WT mice (Table 2).
Histologic examination confirms the relative severity of dis-
ease induced by low-dose DSS. Blinded histologic injury
scores were quantified in the proximal colon from
DSS-treated (2.5%) WT, COX-1–/– and COX-2–/– mice (6
mice per group). DSS administration induced focal
inflammation in WT mice with shortening of the
crypts and small discrete ulcers (Figure 4b). Mucosal
injury was more aggressive in DSS-treated COX-2–/–
mice and was intermediate in COX-1–/– mice (Figure 4,
c and d, Table 3). The most reproducible histologic
abnormalities in DSS-treated mice were crypt damage,
which was significantly worse in COX-1–/– and COX-2–/–
mice compared with WT littermates, and depth of
injury, which was increased in COX-2–/– mice (Table 3).
The total histologic score was highest in DSS-treated
COX-2–/– mice with a significant increase over WT mice
(P < 0.05, Table 3). These observations confirm the
gross findings (Table 2) and indicate that low-dose DSS
induces more active mucosal damage in COX-2–defi-
cient mice with intermediate injury in COX-1–/– mice.
Genetic lack of COX-2 is associated with decreased
colonic production of PGE2 and increased IL-1β
colonic production after low-dose DSS treatment.
COX-2–/– mice treated with 2.5% DSS displayed a sig-
nificant (P < 0.05) decrease in colonic PGE2 production
(Figure 5a) associated with a significant (P < 0.05)
increase in colonic IL-1β secretion (Figure 5b), when
compared with DSS-treated WT mice. The ratio of pro-
tective PGE2/proinflammatory IL-1β was significantly
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Figure 3
Body weight loss (a) and clinical score (b) induced by low-dose
(2.5%) DSS oral treatment in WT, COX-1–/–, and COX-2–/– mice.
Mean ± SEM, n = 7. *P < 0.05 versus WT; +P < 0.05 versus COX-1–/–.
Table 2
Colon, spleen, and hematologic changes in wild-type mice and mice homozygous (–/–)
for COX-1 or COX-2 deficiency treated with low-dose (2.5 %) DSS (day 5 of treatment)
Colon length Colon Spleen weight White blood cells Hematocrit
(mm) weight/length (% (× 10–3/µL) (%)
ratio (mg/cm) body weight)
Water 81 ± 3 26.2 ± 1.3 0.28 ± 0.02 3.7 ± 0.4 52.0 ± 1.0
controls (n = 9)
DSS-treated 73 ± 3 28.4 ± 1.3 0.29 ± 0.02 8.9 ± 0.6B 50.6 ± 0.7
wild-type (n = 6)
DSS-treated 78 ± 4 32.8 ± 4.0 0.42 ± 0.05A,B 10.0 ± 1.1B 48.6 ± 2.2
COX-1–/– (n = 6)
DSS-treated 62 ± 2A,B 34.4± 2.5A,B 0.52 ± 0.04 A,B 17.7 ± 5.5A,B 38.4 ± 4.6A,B
COX-2–/– (n = 6)
AP < 0.05 vs. DSS-treated wild-type. BP < 0.05 vs. water controls.
higher in DSS-treated WT mice (128 ± 20 WT; 18 ± 4
COX-2–/–, P < 0.01). PGE2 production was similar in WT
and COX-2–/– water controls. PGE2 secretion was not
measured in 2.5% DSS-treated COX-1–/– mice because
tissue PGE2 levels were no different from WT controls
after high-dose (10%) DSS treatment (Figure 2).
Partial inhibition of COX-2 by NS-398 exacerbates DSS-
induced colitis in COX-1–deficient mice. Treatment with
the selective COX-2 inhibitor NS-398 (1 mg/kg every
8 hours) did not induce any significant change in the
clinical or histologic scores of DSS-treated (2.5%) WT
and COX-2–/– mice (data not shown). However, NS-
398 treatment consistently increased the clinical
score in DSS-treated COX-1–/– mice when compared
with vehicle-treated DSS-treated COX-1–/– after the
first day of DSS administration (Figure 6); although
the body weight loss component was not affected.
NS-398 also evoked a 20% mortality rate in the COX-
1–/– mice at day 5 of low-dose DSS treatment, where-
as none of the vehicle-treated COX-1–/– mice died. The
histologic score at day 5 of DSS treatment was con-
siderably higher in COX-1–/– mice treated with NS-
398 than in similarly treated WT mice (WT 5.9 ± 2.5
versus COX-1–/– 14.5 ± 1.9, P < 0.01); it achieved levels
comparable with COX-2–/– mice receiving DSS and
NS-398 (15.6 ± 0.9). NS-398 increased colonic histo-
logic scores 28% in COX-1–/– mice (11.3 ± 1.3 vehicle;
14.5 ± 1.9 NS-398) and increased the surface area
ulcerated by histologic assessment by 53% (14.3 ±
4.3% vehicle versus 21.9 ± 3.9 NS-398). NS-398 par-
tially inhibited the production of PGE2 by cultured
colonic tissues (24 hours) in the DSS-treated COX-
1–deficient mice (vehicle treated: 3,583 ± 1,162 pg
PGE2/mg tissue versus NS-398 treated: 1,971 ± 763
pg/mg; P = 0.13). Furthermore, NS-398 did not inhib-
it colonic PGE2 production in the DSS-treated COX-
2–/– mice (vehicle treated: 687 ± 141 pg PGE2/mg tis-
sue versus NS-398 treated: 595 ± 29 pg PGE2/mg
tissues), indicating that NS-398 did not affect COX-
1 activity at doses used. These results suggest that
simultaneous inhibition of both constitutive (by
COX-1 genetic deletion) and inducible (by partial
pharmacologic inhibition by NS-398) COX isoforms
further potentiates experimentally induced colitis.
Discussion
Our results demonstrate that genetic absence of either
the COX-2 or COX-1 isoform exacerbates the severity
of acute mucosal inflammation induced by a chemical
agent that injures the colonic epithelial cells (33). Mice
lacking COX-2 are more severely affected than those
lacking COX-1 in this model, and pharmacologic inhi-
bition of COX-2 potentiates disease in COX-1–/– mice.
We also show that genetic lack of either COX-1 or
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Figure 4
Photomicrographs of the proximal colon of mice treated with low-dose DSS (2.5%)
or water only for 5 days, and a DSS-treated COX-1–/– mouse treated with the selec-
tive COX-2 inhibitor NS-398 (1 mg/kg every 8 hours) for 5 days. (a) WT mouse that
received water (negative control) showing no mucosal damage. (b) WT mouse that
received DSS for 5 days. Focal ulceration is present, but the majority of the mucosa
shows no damage. (c) COX-1–/– mouse that received DSS developed a slightly larg-
er mucosal ulcer. (d) COX-2–/– mouse developed more extensive mucosal ulceration
with inflammation extended into the submucosa. (e) COX-1–/– mouse that received
NS-398 developed extensive colonic ulceration and inflammation. Magnification of
all photomicrographs is ×33.
COX-2 alone does not affect the integrity of the colonic
mucosa in the absence of any inflammatory stimulus.
These results suggest that intrinsic PGs, especially
those induced during inflammation, have a protective
role during intestinal injury.
Under basal conditions, native SPF mice lacking
either the COX-1 or COX-2 isoform do not exhibit
any clinical or histologic signs of spontaneous gas-
trointestinal inflammation, despite a marked defi-
ciency in mucosal PGE2 contents in COX-1–deficient
mice. Twenty percent of COX-2–/– mice developed peri-
tonitis, but these mice had no associated mucosal
damage by gross, histologic, or biochemical criteria.
Our results agree with previous reports that COX-
1–deficient mice fail to develop gastritis (31), and that
selective COX-2 inhibitors used at doses that inhibit
arthritis and pulmonary inflammation do not affect
the integrity of the normal gastric mucosa (17, 27,
28). However, the lack of spontaneous gastrointesti-
nal inflammation in COX-1–/– mice (which have very
low constitutive mucosal PG levels) does not agree
with the results of Redfern et al. (15) who reported
spontaneous gastric and colonic ulceration in rab-
bits passively immunized with anti-PGE1, -PGE2, and
-prostacyclin antibodies. Gastrointestinal inflam-
mation after NSAID exposure is probably the com-
bined result of mucosal PG inhibition and direct
epithelial toxicity (10). Our results argue against a
compensatory increase in constitutive PG production
in COX-1–deficient mice, because basal PGE2 pro-
duction was barely detectable in the gastrointestinal
tract of these mice. Thus our data confirm that nei-
ther COX-1 nor COX-2 alone is essential in maintain-
ing integrity in the gastrointestinal mucosa
in the absence of a preexisting injury. How-
ever, our results do not exclude the possibil-
ity that the simultaneous absence of both
COX-1 and COX-2 isoforms might endanger
the integrity of the gastrointestinal mucosa,
as recently hypothesized (37, 38).
Selective COX-2 deletion leads to enhanced
susceptibility to low-dose DSS–induced
injury relative to all other groups investigat-
ed. This correlated with a selective lack of
increased colonic PGE2 levels with injury.
COX-2 heterozygotes, which have a partial
deficiency in inducible PGE2, displayed an
intermediate phenotype. These results strong-
ly support a protective role for inducible
mucosal PGs during inflammation, which is
in agreement with the reported ability of
exogenous PGE2 to prevent experimental coli-
tis (19). PGE2 inhibits IL-1 and TNF-α secre-
tion by stimulated human (6) and murine
(39) monocytes. This provides a mechanism
of mucosal protection during inflammation
and explains our observation of increased
colonic IL-1β levels in COX-2–/– mice with
DSS-induced colitis when compared with WT
mice, which displayed enhanced PGE2 production but
relatively low IL-1β concentrations. Although deficient
endogenous PGs could adversely affect platelet func-
tion and lead to increased fecal blood loss (which is 1
parameter of our clinical score) (33), our results clearly
demonstrate enhanced colonic injury by objective clin-
ical (weight loss, diarrhea, mortality), gross (colonic
weight and length), biochemical (IL-1β secretion), and
histologic criteria. The increase in colonic PGE2 that we
demonstrated in tissue culture supernatants was not
observed when PGE2 levels were measured in processed
sections of frozen colonic tissues (data not shown).
This is consistent with a recent observation that PGE2
in cecal tissues of DSS-treated mice does not increase
during the treatment period, but rather increases sig-
nificantly 3 days after cessation of DSS administration
during the recovery (19).
Our findings agree with recent reports that selective
inhibition of COX-2 exacerbates trinitrobenzene sul-
fonic acid–induced colitis in rats (30) and delays heal-
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Figure 5
PGE2 levels (a) and IL-1β levels (b)
in 24-hour culture supernatants
of colonic tissues from untreated
(water controls) or DSS-treated
(2.5%) WT and COX-2–/– mice.
The colons were removed, opened
longitudinally, washed in PBS
buffer containing penicillin, strep-
tomycin, and fungizone (P/S/F,
100 U/mL), and kept in cold
serum-free media (RPMI 1640 1×
with P/S/F). The organs were cut
into small pieces in a Petri dish
containing fresh media, and 100
mg of tissues was incubated at
37°C in 1 mL of fresh media for
24 hours. Culture supernatants
were harvested and assayed for
PGE2 secretion by RIA and for IL-
1β by ELISA (Genzyme Diagnos-
tics). Mean ± SEM, n = 7. *P <
0.05 versus WT; +P < 0.05 versus
water controls.
Table 3
Blinded histologic assessment of colonic injury in WT, COX-1–/–, and
COX-2–/– mice treated with 2.5% DSS for 5 days
Percent of Depth of Crypt Total
surface tissue damage histologic 
area ulcerated injuryA scoreA scoreA
WT (n = 6)B 12.5 ± 5.5C 2.1 ± 0.5 3.3 ± 0.5 8.6 ± 1.6
COX-1–/– (n = 6) 14.3 ± 4.3 2.9 ± 0.4 4.7 ± 0.5D 11.3 ± 1.3
COX-2–/– (n = 6) 19.5 ± 3.8 4.2 ± 0.5D 4.6 ± 0.4D 12.6 ± 1.2D
ABased on validated scoring system described in Methods section (34). BFor 1–4
sections per mouse, 6 mice/group. CMean ± SEM. DP < 0.05 versus WT mice.
ing of acetic acid–induced gastric ulcers in mice (29).
Selective COX-2 inhibitors have no effect on small
intestinal crypt survival after irradiation in mice (9).
The absence of involvement of COX-2 in radiation-
induced epithelial damage suggests that the mecha-
nism of injury in that model is different from that trig-
gered by DSS. A recent study showed that DSS
treatment increases the number of COX-2–expressing
lamina propria mononuclear cells, while COX-2 over-
expression remains undetectable in the inflamed
epithelium of those mice (19). Recent in vitro studies
suggest that the role of COX-2 in mucosal injury is
highly variable, depending on the nature of the injuri-
ous stimuli involved. Rat intestinal epithelial cells
transfected with COX-2 exhibit a downregulation of
inducible cytoprotective heat-shock proteins (24),
which are involved in cell death inhibition (40, 41). In
contrast, COX-2 overexpression in rat intestinal
epithelial cells provides cellular resistance against
butyrate-induced apoptosis (42).
Our COX-1–/– mice had almost undetectable basal
PGE2 levels, but their colonic PGE2 concentrations were
equal to those of WT controls after DSS-induced
injury; they had an intermediate sensitivity to inflam-
mation between WT and COX-2–/– mice. The disparity
between PGE2 concentrations in homogenized colonic
tissues and sensitivity to mucosal injury could be
explained by differential production of other protective
arachidonic acid metabolites (i.e., PGE1, prostacyclin,
etc.); or it could be explained by a critically important
role for constitutively produced PGE2 on epithelial
restitution and protection against injurious agents.
Cohn et al. showed that colonic COX-1 is primarily
expressed by epithelial cells (9), and that COX-1 expres-
sion in colonic epithelial cells is diminished after DSS
administration, probably secondary to loss of crypt
epithelial cells (19). The former study demonstrated a
key role for PGs regulated by COX-1 in mediating crypt
stem cell survival after gamma irradiation in mice. Sim-
ilarly, in the stomach, COX-1 plays an important role
in resistance of the gastric mucosa to acute and chron-
ic injury by endotoxin (43). These results suggest that
constitutively produced PGs in gastrointestinal epithe-
lial cells protect against a variety of injurious stimuli in
an autocrine fashion. Inducible PG secretion by acti-
vated mononuclear and mesenchymal cells expressing
COX-2 does not seem to entirely compensate for loss of
epithelial COX-1 expression. However, COX-2–mediat-
ed PG production is clearly important, as demonstrat-
ed by the highly aggressive DSS-induced colitis in COX-
2–/– mice and in COX-1–/– mice treated with the selective
COX-2 inhibitor NS-398. It has been suggested that
COX-2 plays a role in healing rather than in protection
of the colonic mucosa, as in the gastric mucosa (44).
This concept has been strongly suggested by a recent
observation that cecal tissue PGE2 levels are increased
during the recovery period after DSS treatment (19).
However, it is likely that COX-2 also acts through com-
plementary mechanisms. Recently, COX-2 has been
reported to mediate oral immunologic tolerance to a
dietary antigen in T-cell receptor mutant mice (45). In
that model, high levels of COX-2–dependent PGs pro-
duced by lamina propria mononuclear cells act as
immunomodulators in T-lymphocyte responses to the
antigen. This observation suggests that COX-2 may
promote mucosal protection by suppressing patho-
genic cellular immune responses to luminal bacterial
antigens that perpetuate intestinal inflammation (46).
Consistent with observations in a murine model of
absent intestinal trefoil factor (47), biologic effects of
COX isoform deficiency were more apparent at low-dose
than high-dose DSS. The fulminant colitis induced by
10% DSS led to a 50% mortality rate in both COX-1– and
COX-2–deficient mice, whereas responses to 2.5% DSS
administration, which induced very mild inflammation
in WT mice, indicated a more active protective role for
COX-2 than for COX-1. However, both high- and low-
dose DSS–induced injuries were worse in mice with
selective blockade of constitutive or inducible PG syn-
thesis than in WT controls.
Treatment with the selective COX-2 inhibitor NS-398
exacerbated low-dose DSS–induced colitis and enhanced
mortality in COX-1–/– mice. This indicates an additive
protective role for both COX-1 and COX-2 in this model.
Inflammation and colonic PGE2 production in DSS-
treated COX-2–/– mice were not affected by NS-398 treat-
ment, demonstrating that this COX-2 inhibitor did not
substantially affect the activity of the COX-1 isoform.
The absence of an effect of NS-398 on DSS-treated WT
mice may be due to the partial inhibition of COX-2
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Figure 6
Effect of the selective COX-2 inhibitor NS-398 on the clinical score
in 2.5% DSS-treated COX-1–/– mice. NS-398 (1 mg/kg) was injected
intraperitoneally every 8 hours, leading to a cumulative dosage of 3
mg/kg daily. NS-398 was administered starting 2 hours before treat-
ment with 2.5% DSS and for 5 days consecutively until the end of DSS
treatment. Control COX-1–/– mice treated with 2.5% DSS were
administered the vehicle for NS-398 under the same conditions. Ten
to 15 mice per group were investigated. Mean ± SEM. *P < 0.05 ver-
sus vehicle-treated group; **P < 0.01 versus vehicle-treated group.
expression at doses used in this study, as compared with
the total lack of inducible prostaglandins in the colons
of COX-2–/– mutants.
Mice genetically deficient in either the COX-1 or
COX-2 isoform may display compensatory metabolic
pathways. For example, immortalized, nontransformed
lung fibroblasts from COX-1–/– and COX-2–/– mice over-
express the remaining functional COX isoform in
response to IL-1, leading to a relative increase in PGE2
production (48). These cells also overexpress cytosolic
phospholipase A2 in both unstimulated and IL-1-stim-
ulated conditions (48). However, we did not observe
any increase in colonic PGE2 production in DSS-treat-
ed COX-2–/– mice, whereas both WT and COX-1–/– mice
exhibited significant increases. In addition, colonic tis-
sues of COX-1–/– mice contained almost undetectable
levels of PGE2 when compared with the colons from
WT and COX-2–/– mice. These findings strongly suggest
that there are no compensatory pathways induced in
the colons of these knockout mice, although we cannot
rule out such a possibility.
In conclusion, both COX-1 and COX-2 mediate pro-
tection against acute mucosal inflammation, because
absence of either isoform exacerbates DSS-induced
colitis, yet neither isoform is absolutely required for
maintenance of mucosal homeostasis in the absence of
injurious stimuli. Furthermore, simultaneous blockade
of both isoforms by gene deletion of COX-1 and partial
pharmacologic inhibition of COX-2 produced even
greater injury, indicating an additive protective role for
constitutive and inducible PGs. When relatively low
doses of DSS were administered, COX-2–deficient mice
had more aggressive colitis than COX-1–/– mice, sug-
gesting that inducible PGs may be relatively more
important in modulating mucosal protection against
colonic injury than constitutive PGs. The reciprocal
relationship between mucosal PGE2 and IL-1β concen-
trations supports an inhibitory effect of PGE2 on
proinflammatory cytokine production, whereas the
beneficial effect of COX-1, which is predominantly pro-
duced by crypt epithelial cells (9), suggests a protective
effect in epithelial integrity. In our model of acute
colonic injury, COX-2–mediated PG production plays
a beneficial rather than a proinflammatory role, sug-
gesting that selective COX-2 pharmacologic inhibitors
should be avoided in patients with established intes-
tinal inflammation. Similar conclusions have been
reached in a recent study showing that COX-2 exhibits
anti-inflammatory properties in a rat model of pleurisy
(49). The complex, interactive mechanisms of how con-
stitutive and inducible PGs prevent intestinal inflam-
mation remain to be determined. These mechanisms
can be dissected using complementary approaches
afforded by selective pharmacologic inhibitors and
genetic deletion of COX-1 and COX-2 gene expression.
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